Column Group’s Tenaya Therapeutics TNYA Stock Holding History

Column Group’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,400,290	Closed	-$6.69M	–	5
2025 Q4	$6.69M	Hold	9,400,290	–	–	8.08%	3
2025 Q3	$14.9M	Hold	9,400,290	–	–	18.35%	3
2025 Q2	$5.74M	Hold	9,400,290	–	–	8.74%	4
2025 Q1	$5.36M	Hold	9,400,290	–	–	12.12%	3
2024 Q4	$13.4M	Hold	9,400,290	–	–	24.12%	2
2024 Q3	$18.1M	Hold	9,400,290	–	–	26.08%	2
2024 Q2	$29.1M	Hold	9,400,290	–	–	40.88%	1
2024 Q1	$49.2M	Hold	9,400,290	–	–	30.62%	1
2023 Q4	$30.5M	Hold	9,400,290	–	–	20.12%	3
2023 Q3	$24M	Hold	9,400,290	–	–	15.92%	3
2023 Q2	$55.2M	Hold	9,400,290	–	–	21.42%	2
2023 Q1	$26.8M	Hold	9,400,290	–	–	9.69%	4
2022 Q4	$18.9M	Hold	9,400,290	–	–	6.29%	5
2022 Q3	$27.3M	Hold	9,400,290	–	–	6.03%	4
2022 Q2	$52.9M	Hold	9,400,290	–	–	11.26%	3
2022 Q1	$111M	Hold	9,400,290	–	–	20.53%	2
2021 Q4	$178M	Hold	9,400,290	–	–	24.23%	2
2021 Q3	$194M	Buy	+9,400,290	New	+$202M	22.08%	2

Other funds holding TNYA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BGM

Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $140M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Column Group's TNYA Position: Q1 2026 in Review

Column Group sold out of Tenaya Therapeutics (TNYA) in Q1 2026, closing a stake of 9,400,290 shares — an estimated $6.69M sold.

Column Group first reported a position in TNYA in Q3 2021 and held it in 18 quarters. The position peaked at $194M in Q3 2021. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

Column Group reported no remaining Tenaya Therapeutics position as of Q1 2026 after selling out during the quarter.
Column Group sold 9,400,290 Tenaya Therapeutics shares in Q1 2026, an estimated $6.69M.
Column Group first reported a position in Tenaya Therapeutics in Q3 2021 and held it in 18 quarters.
Column Group's Tenaya Therapeutics position peaked at $194M in Q3 2021.
103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on Column Group's 13F filing for Q1 2026, filed 18 May 2026.